Targeting immunogenic cell death for glioma immunotherapy

Tatiana A Mishchenko; Victoria D Turubanova; Ekaterina N Gorshkova; Olga Krysko; Maria V Vedunova; Dmitri V Krysko

doi:10.1016/j.trecan.2023.10.005

Targeting immunogenic cell death for glioma immunotherapy

Trends Cancer. 2024 Jan;10(1):8-11. doi: 10.1016/j.trecan.2023.10.005. Epub 2023 Nov 14.

Authors

Tatiana A Mishchenko¹, Victoria D Turubanova², Ekaterina N Gorshkova¹, Olga Krysko³, Maria V Vedunova¹, Dmitri V Krysko⁴

Affiliations

¹ Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
² Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia; Neuroscience Research Institute, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
³ Cell Death Investigation and Therapy Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
⁴ Cell Death Investigation and Therapy Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent, Ghent, Belgium. Electronic address: dmitri.krysko@ugent.be.

PMID: 37973489
DOI: 10.1016/j.trecan.2023.10.005

Abstract

Immunogenic cell death (ICD) arouses great interest in targeting glioma, the most common primary brain tumor, to achieve boosted immunotherapy. We discuss the unexpected findings on the induction of Th17 immunity by ICD and propose the best design for dendritic cell (DC)-based vaccines loaded with whole glioma lysates obtained after ICD inducers.

Keywords: DC vaccines; Th17; cancer; glioblastoma; tumor microenvironment; whole tumor lysates.

MeSH terms

Antineoplastic Agents* / pharmacology
Glioma* / pathology
Glioma* / therapy
Humans
Immunogenic Cell Death
Immunotherapy

Substances

Antineoplastic Agents

Grants and funding

22-15-00376,/Russian Science Foundation